US 12,678,408 · Application 19/545,594 · Granted Jul 14, 2026

US 12,678,408

Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine

Estimated expiration

June 29, 2036

9y 275d remaining

Confidence: medium

Could not fetch continuity data for application 17984290: Resource not found (404)
Could not fetch continuity data for application 17667674: Resource not found (404)
Could not fetch continuity data for application 17386089: Resource not found (404)
Could not fetch continuity data for application 17148765: Resource not found (404)
Could not fetch continuity data for application 16923139: Resource not found (404)
Could not fetch continuity data for application 16690272: Resource not found (404)
Application 19048549 has not been granted a patent number
Application 19451185 has not been granted a patent number

Earliest effective filing

Jun 29, 2016

+ 20 years

Jun 29, 2036

PTA +0d

Jun 29, 2036

TD applied

Jun 29, 2036

Final

Jun 29, 2036

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date: February 20, 2026
Earliest effective filing: June 29, 2016
Issue date: July 14, 2026
PTA: 0 days
Base expiry (before PTA): June 29, 2036

June 29, 2016 + 20 years = June 29, 2036

Continuation of application 19/048,549, filed Feb 7, 2025
Continuation of application 18/782,290, filed Jul 24, 2024
Continuation of application 18/539,583, filed Dec 14, 2023
Continuation of application 18/204,012, filed May 31, 2023
Continuation of application 17/984,290, filed Nov 10, 2022
Continuation of application 17/667,674, filed Feb 9, 2022
Continuation of application 17/386,089, filed Jul 27, 2021
Continuation of application 17/148,765, filed Jan 14, 2021
Continuation of application 16/923,139, filed Jul 8, 2020
Continuation of application 16/690,272, filed Nov 21, 2019
Continuation of application 15/197,491, filed Jun 29, 2016
Continuation of application 17/984,290, filed Nov 10, 2022
Continuation of application 17/667,674, filed Feb 9, 2022
Continuation of application 17/386,089, filed Jul 27, 2021
Continuation of application 17/148,765, filed Jan 14, 2021
Continuation of application 16/923,139, filed Jul 8, 2020
Continuation of application 16/690,272, filed Nov 21, 2019
Continuation of application 15/197,491, filed Jun 29, 2016
Continuation of application 18/204,012, filed May 31, 2023
Continuation of application 17/984,290, filed Nov 10, 2022
Continuation of application 17/667,674, filed Feb 9, 2022
Continuation of application 17/386,089, filed Jul 27, 2021
Continuation of application 17/148,765, filed Jan 14, 2021
Continuation of application 16/923,139, filed Jul 8, 2020
Continuation of application 16/690,272, filed Nov 21, 2019
Continuation of application 15/197,491, filed Jun 29, 2016
Continuation of application 18/539,583, filed Dec 14, 2023
Continuation of application 18/204,012, filed May 31, 2023
Continuation of application 17/984,290, filed Nov 10, 2022
Continuation of application 17/667,674, filed Feb 9, 2022
Continuation of application 17/386,089, filed Jul 27, 2021
Continuation of application 17/148,765, filed Jan 14, 2021
Continuation of application 16/923,139, filed Jul 8, 2020
Continuation of application 16/690,272, filed Nov 21, 2019
Continuation of application 15/197,491, filed Jun 29, 2016
Continuation of application 18/782,290, filed Jul 24, 2024
Continuation of application 18/539,583, filed Dec 14, 2023
Continuation of application 18/204,012, filed May 31, 2023
Continuation of application 17/984,290, filed Nov 10, 2022
Continuation of application 17/667,674, filed Feb 9, 2022
Continuation of application 17/386,089, filed Jul 27, 2021
Continuation of application 17/148,765, filed Jan 14, 2021
Continuation of application 16/923,139, filed Jul 8, 2020
Continuation of application 16/690,272, filed Nov 21, 2019
Continuation of application 15/197,491, filed Jun 29, 2016
PRO62/317,286 — Provisional — not used for base term
PRO62/301,429 — Provisional — not used for base term
PRO62/298,373 — Provisional — not used for base term
PRO62/187,113 — Provisional — not used for base term
PRO62/317,286 — Provisional — not used for base term
PRO62/301,429 — Provisional — not used for base term
PRO62/298,373 — Provisional — not used for base term
PRO62/187,113 — Provisional — not used for base term
PRO62/317,286 — Provisional — not used for base term
PRO62/301,429 — Provisional — not used for base term
PRO62/298,373 — Provisional — not used for base term
PRO62/187,113 — Provisional — not used for base term
PRO62/317,286 — Provisional — not used for base term
PRO62/301,429 — Provisional — not used for base term
PRO62/298,373 — Provisional — not used for base term
PRO62/187,113 — Provisional — not used for base term
PRO62/317,286 — Provisional — not used for base term
PRO62/301,429 — Provisional — not used for base term
PRO62/298,373 — Provisional — not used for base term
PRO62/187,113 — Provisional — not used for base term
PRO62/317,286 — Provisional — not used for base term
PRO62/301,429 — Provisional — not used for base term
PRO62/298,373 — Provisional — not used for base term
PRO62/187,113 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to June 29, 2036

US 12,678,408· Application 19/545,594(from application 19/545,594)Capping patent
Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine
Filing date
Feb 20, 2026
Earliest effective filing
Jun 29, 2016
Issue date
Jul 14, 2026
PTA
0 days
Calculated expiration
Jun 29, 2036
Continuation of 19/048,549, filed Feb 7, 2025
Continuation of 18/782,290, filed Jul 24, 2024
Continuation of 18/539,583, filed Dec 14, 2023
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 18/539,583, filed Dec 14, 2023
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 18/782,290, filed Jul 24, 2024
Continuation of 18/539,583, filed Dec 14, 2023
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Jun 29, 2016 + 20y = Jun 29, 2036
US APP:19048549(from application 19/048,549)
Could not resolve calculation details
US 12,629,338· Application 19/451,093(from application 19/451,093)
Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine
Filing date
Jan 16, 2026
Earliest effective filing
Jun 29, 2016
Issue date
May 19, 2026
PTA
0 days
Calculated expiration
Jun 29, 2036
Continuation of 19/048,549, filed Feb 7, 2025
Continuation of 18/782,290, filed Jul 24, 2024
Continuation of 18/539,583, filed Dec 14, 2023
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 18/539,583, filed Dec 14, 2023
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 18/782,290, filed Jul 24, 2024
Continuation of 18/539,583, filed Dec 14, 2023
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Jun 29, 2016 + 20y = Jun 29, 2036
US APP:19451185(from application 19/451,185)
Could not resolve calculation details
US 12,661,323· Application 19/461,014(from application 19/461,014)
Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine
Filing date
Jan 27, 2026
Earliest effective filing
Jun 29, 2016
Issue date
Jun 23, 2026
PTA
0 days
Calculated expiration
Jun 29, 2036
Continuation of 19/048,549, filed Feb 7, 2025
Continuation of 18/782,290, filed Jul 24, 2024
Continuation of 18/539,583, filed Dec 14, 2023
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 18/539,583, filed Dec 14, 2023
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Continuation of 18/782,290, filed Jul 24, 2024
Continuation of 18/539,583, filed Dec 14, 2023
Continuation of 18/204,012, filed May 31, 2023
Continuation of 17/984,290, filed Nov 10, 2022
Continuation of 17/667,674, filed Feb 9, 2022
Continuation of 17/386,089, filed Jul 27, 2021
Continuation of 17/148,765, filed Jan 14, 2021
Continuation of 16/923,139, filed Jul 8, 2020
Continuation of 16/690,272, filed Nov 21, 2019
Continuation of 15/197,491, filed Jun 29, 2016
Jun 29, 2016 + 20y = Jun 29, 2036

Notes (1)

[TD_REFS_TRUNCATED] Found 6 TD references; resolving first 5 only

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

The prosecution record for your AI

Application 19/545,594 · US 12,678,408

You have the date. Your AI can have the file.

PatentReply compiles the prosecution history behind US 12,678,408: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new public application a month is free. The first compile takes a few minutes.

Connect PatentReply See the evidence

Strategy and filing changes require your approval.

Look up another patentWho owns this patent?

Permanent link

www.patentreply.ai/tools/patent-expiration/US12678408

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.

Estimated expiration

Calculation details

Base term

Continuity chain(69 links)

Terminal disclaimers

Referenced patents(5)

Notes (1)

You have the date. Your AI can have the file.